Annuncio • Nov 27
Premier, Inc.(NasdaqGS:PINC) dropped from S&P Global BMI Index Premier, Inc.(NasdaqGS:PINC) dropped from S&P Global BMI Index Annuncio • Nov 19
CurvaFix Expands National Market Access - Awarded Technology Breakthrough Designation with Premier Inc. for General Orthopedic Trauma Products CurvaFix, Inc. announced it has been awarded a Technology Breakthrough Designation for General Orthopedic Trauma Products with Premier, Inc. Premier offers Breakthrough Technology designations to innovations that offer a major advantage in terms of patient safety, clinical outcomes and operational efficiencies. The CurvaFix System is purpose-built to expand surgical options in challenging fracture scenarios, including curved or narrow pelvic corridors, pathological bone, intersecting fixation pathways, and indwelling and adjacent hardware. The CurvaFix System are purpose-built to expand surgical option in challenging fracture scenarios, including curved or narrow pelvic corridors, pathological Bone, intersecting fixation pathways,and indwelling and adjacent hardware". Annuncio • Oct 14
Premier, Inc. to Report Q1, 2026 Results on Nov 04, 2025 Premier, Inc. announced that they will report Q1, 2026 results at 6:30 AM, US Eastern Standard Time on Nov 04, 2025 Annuncio • Sep 24
Premier to Go Private in USD 2.6 Billion Deal with Patient Square Premier Inc. has agreed to be acquired by local investment firm Patient Square Capital in a transaction valued at some USD 2.6 billion (EUR 2.22 billion). Under its terms, shareholders will receive USD 28.25 per share in cash, or a 23.8% premium over the company’s 60-day average closing price as of September 5, according to a statement on September 22, 2025. Premier's board chair Richard Statuto said the decision follows a thorough review of strategic alternatives, emphasising the transaction delivers immediate value to shareholders while positioning Premier for long-term growth with added financial resources. CEO Michael Alkire noted that going private will provide greater flexibility to expand the company’s technology and services as the health care landscape evolves. Patient Square said it sees significant potential in Premier’s supply chain, data, and consulting solutions. The transaction, pending shareholder and regulatory approvals, is expected to close in early 2026, after which Premier’s stock will be delisted. Annuncio • Sep 22
An affiliate of Patient Square Capital, LP entered into definitive agreement to acquire Premier, Inc. (NasdaqGS:PINC) for $2.4 billion. An affiliate of Patient Square Capital, LP entered into definitive agreement to acquire Premier, Inc. (NasdaqGS:PINC) for $2.4 billion on September 21, 2025. A cash consideration valued at $28.25 per share will be paid by Patient Square Capital, LP. In connection with the transaction, Premier will suspend the declaration and distribution of common stock dividends in future quarters. Upon completion of the transaction, Premier will be a private company, and Premier common stock will no longer be listed or traded on any public exchange.
Premier will be required to pay a termination fee to Patient Square equal to approximately $66.21 million if the Merger Agreement is terminated and Patient Square will be required to pay a termination fee to the Premier equal to approximately $168.55
The deal is subject to approval by Premier board of directors, stockholders, satisfaction of regulatory approvals, the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended and other customary closing conditions. The Board of Directors of Premier, Inc. formed a special committee for the transaction. The deal has been unanimously approved by Premier’s Board of Directors. The transaction is not subject to a financing condition. The transaction is expected to close by the first quarter of calendar year 2026. Post completion, the Premier Class A Common Stock will be delisted from the NASDAQ Global Select Market and deregistered
Goldman Sachs & Co. LLC and BofA Securities, Inc. acted as financial advisor for Premier, Inc. Daniel A. Neff, Mark Gordon and Meng Lu of Wachtell, Lipton, Rosen & Katz LLP and Daniel Wolf, P.C., Maggie D. Flores, P.C., Zach Miller and Ned Schultheis of Kirkland & Ellis LLP acted as legal advisor for Patient Square Capital, LP. Ropes & Gray LLP acted as legal advisor for Patient Square Capital, LP. Jefferies LLC and Santander US Capital Markets LLC acted as financial advisor for Patient Square Capital, LP. Cravath, Swaine & Moore LLP acted as legal advisor to the Transaction Committee of the Board of Directors. Joele Frank acted as strategic communications advisor to Premier. Perella Weinberg Partners LP is serving as debt capital markets advisor to Patient Square. Annuncio • Sep 10
Premier, Inc. Appoints Bruce Radcliff as President of Supply Chain Services, Effective September 1 Premier, Inc. announced that it has named Bruce Radcliff as President of Supply Chain Services, effective September 1. In this role, Radcliff oversees Premier’s core supply chain business including sourcing, contract management, operations and business analytics. Radcliff is a seasoned executive with more than 15 years of experience within large healthcare providers and over a decade of supply chain leadership. He joined Premier in May 2023 as Group Vice President of Strategic Sourcing and has helped enhance the competitiveness and differentiation of the company’s group purchasing business by bringing a strong provider perspective. Prior to joining Premier, Radcliff led supply chain operations for Advocate Aurora Health, a Premier member health system with more than $15 billion in revenue. Under Radcliff’s leadership, the health system minimized product shortages and their impacts on clinicians and patient care. He also oversaw all aspects of the organization’s supply chain operations and functions including sourcing, site operations, capital, purchasing, distribution, service contracting, data integrity, analytics and supply chain technology. Annuncio • Aug 21
Premier, Inc., Annual General Meeting, Dec 05, 2025 Premier, Inc., Annual General Meeting, Dec 05, 2025. Declared Dividend • Aug 20
Fourth quarter dividend of US$0.21 announced Dividend of US$0.21 is the same as last year. Ex-date: 29th August 2025 Payment date: 15th September 2025 Dividend yield will be 3.3%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is not covered by earnings (123% earnings payout ratio). However, it is well covered by cash flows (22% cash payout ratio). The dividend has increased by an average of 2.0% per year over the past 5 years and payments have been stable during that time. The company's earnings per share (EPS) would need to grow by 37% to bring the payout ratio under control. EPS is expected to grow by 51% over the next 3 years, which is sufficient to bring the dividend into a sustainable range. New Risk • Aug 19
New minor risk - Dividend sustainability The dividend is not well covered by earnings. Payout ratio: 123% Dividend yield: 3.2% This is considered a minor risk. Companies that pay out too much of their earnings are at risk of having to reduce or cut their dividend in future. If earnings growth slows or earnings fall, then there may not be enough earnings to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. However, this risk is mitigated by the fact the dividend is covered by cash flows. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (123% payout ratio). Profit margins are more than 30% lower than last year (6.1% net profit margin). Annuncio • Jul 29
Premier, Inc. to Report Q4, 2025 Results on Aug 19, 2025 Premier, Inc. announced that they will report Q4, 2025 results at 6:30 AM, US Eastern Standard Time on Aug 19, 2025 New Risk • May 23
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 2.8% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 2.8% per year for the foreseeable future. Minor Risk Large one-off items impacting financial results. Major Estimate Revision • May 20
Consensus EPS estimates increase by 24% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from US$0.427 to US$0.53. Revenue forecast steady at US$987.7m. Net income forecast to shrink 22% next year vs 22% growth forecast for Healthcare industry in the US . Consensus price target up from US$20.71 to US$21.29. Share price was steady at US$23.10 over the past week. Reported Earnings • May 07
Third quarter 2025 earnings: EPS and revenues exceed analyst expectations Third quarter 2025 results: EPS: US$0.32 (up from US$0.36 loss in 3Q 2024). Revenue: US$261.4m (down 24% from 3Q 2024). Net income: US$27.8m (up US$68.0m from 3Q 2024). Profit margin: 11% (up from net loss in 3Q 2024). Revenue exceeded analyst estimates by 8.0%. Earnings per share (EPS) also surpassed analyst estimates by 20%. Revenue is expected to decline by 6.8% p.a. on average during the next 3 years, while revenues in the Healthcare industry in the US are expected to grow by 7.0%. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Annuncio • May 06
Premier, Inc. Updates Earnings Guidance for the Fiscal 2025 Premier, Inc. updated earnings guidance for the fiscal 2025. For the period, the company currently expects total net revenue excluding Contigo Health to be in the range of $955 million to $995 million against previous guidance of $940 million to $1.01 billion. No change to midpoint. Declared Dividend • Apr 28
Second quarter dividend of US$0.21 announced Dividend of US$0.21 is the same as last year. Ex-date: 30th May 2025 Payment date: 15th June 2025 Dividend yield will be 4.2%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is not covered by earnings (220% earnings payout ratio). However, it is well covered by cash flows (21% cash payout ratio). The dividend has increased by an average of 2.0% per year over the past 5 years and payments have been stable during that time. The company's earnings per share (EPS) would need to grow by 144% to bring the payout ratio under control. EPS is expected to grow by 151% over the next 3 years, which is sufficient to bring the dividend into a sustainable range. Annuncio • Apr 25
Premier, Inc. Declares Quarterly Cash Dividend, Payable No Later Than June 15, 2025 Premier, Inc. announced that its Board of Directors declared a cash dividend of $0.21 per share of Class A common stock issued and outstanding. The cash dividend will be payable no later than June 15, 2025, to stockholders of record as of the close of business on June 1, 2025. Annuncio • Apr 22
Premier, Inc. Application Is Under Construction in Epic Toolbox Premier, Inc. announced that one of its AI-powered applications, Stanson HealthCodingCare, is Under Construction in Toolbox on Epic Showroom. The Under Construction designation highlights products that will become available once development is released by Epic and participating developers. Premier's Stanson Health team will preview the app during Epic's XGM (April 28 - May 2, 2025) and meet with Epic customers to showcase its capabilities. Premier's Stanson Health app is designed to make it easier for providers to optimize value-based care performance through smarter, automated workflows. The app is powered by clinician-trained, generative AI and is designed to seamlessly integrate into Epic's Risk Adjustment workflows. The app helps clinical teams identify Hierarchical Condition Categories (HCC) required by the Centers for Medicare & Medicaid Services (CMS) for accurate risk adjustment and reimbursement in Medicare Advantage and other value-based care programs. Real-time AI Insights to Improve Coding Accuracy: Expected to go live in late 2025 for Epic users, the app will use real-time data from the chart, including clinical notes, to: Suggest accurate HCC coding opportunities using up-to-date clinical insights; Empower physicians and coding teams to act seamlessly on documentation gaps; Reduce manual coding efforts and streamline workflows; Improve claim accuracy and speed up payment cycles. A 2020 JAMA study found that 39% of HCCs were not fully documented, leading to undercoding and revenue loss for providers. Premier's AI-powered HCC app helps close these gaps efficiently. Annuncio • Apr 10
Premier, Inc. to Report Q3, 2025 Results on May 06, 2025 Premier, Inc. announced that they will report Q3, 2025 results at 6:30 AM, US Eastern Standard Time on May 06, 2025 Upcoming Dividend • Feb 21
Upcoming dividend of US$0.21 per share Eligible shareholders must have bought the stock before 28 February 2025. Payment date: 15 March 2025. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 4.4%. Within top quartile of American dividend payers (4.4%). Higher than average of industry peers (1.9%). Major Estimate Revision • Feb 11
Consensus EPS estimates fall by 61% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from US$1.33 to US$0.516 per share. Revenue forecast steady at US$987.5m. Net income forecast to grow 136% next year vs 26% growth forecast for Healthcare industry in the US. Consensus price target down from US$20.86 to US$19.79. Share price fell 3.1% to US$18.52 over the past week. Annuncio • Feb 05
Premier, Inc. Announces Impairment Charges for the Second Quarter of 2025 Premier, Inc. announced impairment charges for the second quarter of 2025. For the period, the company's impairment charge to goodwill of $127 million related to data and technology business in the Performance Services segment. Reported Earnings • Feb 04
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Second quarter 2025 results: US$0.60 loss per share (down from US$0.45 profit in 2Q 2024). Revenue: US$240.3m (down 28% from 2Q 2024). Net loss: US$56.6m (down 204% from profit in 2Q 2024). Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) were also behind analyst expectations. Revenue is expected to decline by 6.8% p.a. on average during the next 3 years, while revenues in the Healthcare industry in the US are expected to grow by 7.0%. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings. Annuncio • Feb 04
Premier, Inc. Provides Earnings Guidance for the Fiscal 2025 Premier, Inc. provided earnings guidance for the fiscal 2025. The company currently expects Total Net Revenue Excluding Contigo Health to be in the range of $940 million to $1.01 billion against previous guidance of $930 million to $1.02 billion. Declared Dividend • Jan 27
First quarter dividend of US$0.21 announced Dividend of US$0.21 is the same as last year. Ex-date: 28th February 2025 Payment date: 15th March 2025 Dividend yield will be 3.7%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (62% earnings payout ratio) and cash flows (39% cash payout ratio). The dividend has increased by an average of 2.5% per year over the past 4 years and payments have been stable during that time. EPS is expected to decline by 29% over the next 3 years. However, it would need to fall by 31% to increase the payout ratio to a potentially unsustainable range. Annuncio • Jan 24
Premier, Inc. Declares Quarterly Cash Dividend, Payable on March 15, 2025 Premier, Inc. announced that its Board of Directors declared a cash dividend of $0.21 per share of Class A common stock issued and outstanding. The cash dividend will be payable on March 15, 2025, to stockholders of record as of the close of business on March 1, 2025. Annuncio • Jan 17
Premier, Inc. to Report Q2, 2025 Results on Feb 04, 2025 Premier, Inc. announced that they will report Q2, 2025 results at 6:30 AM, US Eastern Standard Time on Feb 04, 2025 Annuncio • Dec 03
Premier, Inc. Announces Executive Changes Premier, Inc. announced that it has named David (Dave) Zito as President, Performance Services, effective December 6, 2024. Zito will oversee Premier’s Performance Services segment, including the continued development and growth of the company’s enterprise-wide, AI-enabled technology businesses and Premier’s consulting practice. He will report to Michael J. Alkire, Premier’s President and CEO. Zito is a seasoned healthcare executive, with expertise across provider networks, payer systems, life sciences and healthcare managed services. He served as the Chief Growth Officer for Guidehouse, where he was responsible for leading investments in new markets and opportunities, developing innovative technology solutions and business process management, and driving large-scale, cross-segment collaboration. This included oversight of the Managed Services and Advanced Solutions business units, along with the Sales, Marketing and Employee Experience functions. Zito previously served as the Healthcare Practice lead at Navigant Consulting. The company also announced that Leigh Anderson, who currently serves as Chief Operating Officer, will resign from his position, effective December 31, 2024, and is expected to provide consulting services to the company through March 31, 2025. As a consultant, he will support the leadership transition for Performance Services, support Premier’s digital supply chain solutions and assist with other business needs, as requested. Oversight of Premier’s technology and consulting services will transition from Anderson to Zito on December 6. Management of Premier’s group purchasing organization will remain with Premier’s Senior Vice President of Supply Chain, Bruce Radcliff, who will also report directly to Alkire, effective December 6. The company does not intend to fill the COO role. Upcoming Dividend • Nov 22
Upcoming dividend of US$0.21 per share Eligible shareholders must have bought the stock before 29 November 2024. Payment date: 15 December 2024. Payout ratio is a comfortable 62% and this is well supported by cash flows. Trailing yield: 3.7%. Lower than top quartile of American dividend payers (4.3%). Higher than average of industry peers (1.6%). Major Estimate Revision • Nov 12
Consensus EPS estimates increase by 58% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from US$977.5m to US$988.5m. EPS estimate increased from US$0.838 to US$1.32 per share. Net income forecast to shrink 18% next year vs 32% growth forecast for Healthcare industry in the US . Consensus price target up from US$19.50 to US$21.25. Share price was steady at US$22.97 over the past week. Price Target Changed • Nov 06
Price target increased by 7.1% to US$20.88 Up from US$19.50, the current price target is an average from 8 analysts. New target price is 11% below last closing price of US$23.34. Stock is up 18% over the past year. The company is forecast to post earnings per share of US$1.32 for next year compared to US$1.05 last year. Reported Earnings • Nov 06
First quarter 2025 earnings: EPS and revenues exceed analyst expectations First quarter 2025 results: EPS: US$0.72 (up from US$0.38 in 1Q 2024). Revenue: US$248.1m (down 22% from 1Q 2024). Net income: US$72.4m (up 62% from 1Q 2024). Profit margin: 29% (up from 14% in 1Q 2024). Revenue exceeded analyst estimates by 6.6%. Earnings per share (EPS) also surpassed analyst estimates significantly. Revenue is expected to decline by 8.1% p.a. on average during the next 3 years, while revenues in the Healthcare industry in the US are expected to grow by 6.7%. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings. Annuncio • Nov 05
Premier, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2025 Premier, Inc. reaffirmed earnings guidance for the fiscal year 2025. For the year, the company expected Total Net Revenue Excluding Contigo Health of $930 million to $1.02 billion. Declared Dividend • Oct 28
Fourth quarter dividend of US$0.21 announced Dividend of US$0.21 is the same as last year. Ex-date: 29th November 2024 Payment date: 15th December 2024 Dividend yield will be 4.2%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (80% earnings payout ratio) and cash flows (38% cash payout ratio). The dividend has increased by an average of 2.5% per year over the past 4 years and payments have been stable during that time. EPS is expected to decline by 11% over the next 3 years. A fall of 11% would increase the payout ratio to a potentially unsustainable range, which means the dividend may be at risk. Annuncio • Oct 25
Premier, Inc. Declares Quarterly Cash Dividend, Payable on December 15, 2024 Premier, Inc. announced that its board of directors declared a quarterly cash dividend of $0.21 per share of Class A common stock issued and outstanding. The cash dividend will be payable on December 15, 2024, to stockholders of record as of the close of business on December 1, 2024. Annuncio • Oct 22
Premier, Inc., Annual General Meeting, Dec 06, 2024 Premier, Inc., Annual General Meeting, Dec 06, 2024. Annuncio • Oct 10
Premier, Inc. to Report Q1, 2025 Results on Nov 05, 2024 Premier, Inc. announced that they will report Q1, 2025 results at 6:30 AM, US Eastern Standard Time on Nov 05, 2024 Recent Insider Transactions Derivative • Sep 29
President notifies of intention to sell stock Michael Alkire intends to sell 19k shares in the next 90 days after lodging an Intent To Sell Form on the 27th of September. If the sale is conducted around the recent share price of US$20.05, it would amount to US$376k. For the year to June 2018, Michael's total compensation was 14% salary and 86% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since December 2023, Michael's direct individual holding has increased from 232.95k shares to 578.14k. There have been no trades via on-market transactions or options from company insiders in the last 12 months. Recent Insider Transactions Derivative • Sep 05
Independent Director notifies of intention to sell stock Jody Davids intends to sell 14k shares in the next 90 days after lodging an Intent To Sell Form on the 3rd of September. If the sale is conducted around the recent share price of US$20.28, it would amount to US$276k. Since December 2023, Jody has owned 15.56k shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months. Major Estimate Revision • Aug 28
Consensus revenue estimates fall by 21% The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$1.24b to US$978.0m. EPS estimate fell from US$1.47 to US$0.85 per share. Net income forecast to shrink 27% next year vs 29% growth forecast for Healthcare industry in the US . Consensus price target down from US$21.89 to US$19.88. Share price fell 2.2% to US$19.79 over the past week. Price Target Changed • Aug 26
Price target decreased by 9.2% to US$19.88 Down from US$21.89, the current price target is an average from 8 analysts. New target price is approximately in line with last closing price of US$20.02. Stock is down 8.4% over the past year. The company is forecast to post earnings per share of US$0.85 for next year compared to US$1.05 last year. Annuncio • Aug 22
Premier, Inc. Announces Chief Financial Officer Changes Premier, Inc. announced appointment of Glenn Coleman as chief financial officer, effective November 11, 2024. Coleman will take over from Craig McKasson, who will be retiring on December 31, 2024, and will continue to provide strategic advisory services to the company until 2026. Currently serving as the Executive Vice President and Chief Financial Officer at Dentsply Sirona, Coleman brings more than 30 years of financial and industry experience to his new role. His previous leadership positions include tenures at Integra LifeSciences, Curtiss-Wright, and Alcatel-Lucent. Reported Earnings • Aug 22
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: EPS: US$1.05 (down from US$1.47 in FY 2023). Revenue: US$1.35b (flat on FY 2023). Net income: US$119.5m (down 32% from FY 2023). Profit margin: 8.9% (down from 13% in FY 2023). Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) also surpassed analyst estimates by 29%. Revenue is expected to decline by 6.5% p.a. on average during the next 3 years, while revenues in the Healthcare industry in the US are expected to grow by 6.8%. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 21
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: EPS: US$1.05 (down from US$1.47 in FY 2023). Revenue: US$1.35b (flat on FY 2023). Net income: US$119.5m (down 32% from FY 2023). Profit margin: 8.9% (down from 13% in FY 2023). Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) also surpassed analyst estimates by 29%. Revenue is expected to decline by 6.5% p.a. on average during the next 3 years, while revenues in the Healthcare industry in the US are expected to grow by 6.8%. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 21
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: EPS: US$1.05 (down from US$1.47 in FY 2023). Revenue: US$1.35b (flat on FY 2023). Net income: US$119.5m (down 32% from FY 2023). Profit margin: 8.9% (down from 13% in FY 2023). Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) also surpassed analyst estimates by 29%. Revenue is expected to decline by 6.5% p.a. on average during the next 3 years, while revenues in the Healthcare industry in the US are expected to grow by 6.8%. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 21
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: EPS: US$1.05 (down from US$1.47 in FY 2023). Revenue: US$1.35b (flat on FY 2023). Net income: US$119.5m (down 32% from FY 2023). Profit margin: 8.9% (down from 13% in FY 2023). Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) also surpassed analyst estimates by 29%. Revenue is expected to decline by 6.5% p.a. on average during the next 3 years, while revenues in the Healthcare industry in the US are expected to grow by 6.8%. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 21
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: EPS: US$1.05 (down from US$1.47 in FY 2023). Revenue: US$1.35b (flat on FY 2023). Net income: US$119.5m (down 32% from FY 2023). Profit margin: 8.9% (down from 13% in FY 2023). Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) also surpassed analyst estimates by 29%. Revenue is expected to decline by 6.5% p.a. on average during the next 3 years, while revenues in the Healthcare industry in the US are expected to grow by 6.8%. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 21
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: EPS: US$1.05 (down from US$1.47 in FY 2023). Revenue: US$1.35b (flat on FY 2023). Net income: US$119.5m (down 32% from FY 2023). Profit margin: 8.9% (down from 13% in FY 2023). Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) also surpassed analyst estimates by 29%. Revenue is expected to decline by 6.5% p.a. on average during the next 3 years, while revenues in the Healthcare industry in the US are expected to grow by 6.8%. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings. Annuncio • Aug 21
Premier, Inc. Announces Executive Changes Premier, Inc. announced appointment of Glenn Coleman as chief administrative, effective November 11, 2024. Coleman will take over from Craig McKasson, who will be retiring on December 31, 2024, and will continue to provide strategic advisory services to the company until 2026. Currently serving as the Executive Vice President and Chief Financial Officer at Dentsply Sirona, Coleman brings more than 30 years of financial and industry experience to his new role. His previous leadership positions include tenures at Integra LifeSciences, Curtiss-Wright, and Alcatel-Lucent. Annuncio • Aug 20
Premier, Inc. Provides Earnings Guidance for the Fiscal Year 2025 Premier, Inc. provided earnings guidance for the fiscal year 2025. For the year, the company expects total net revenue excluding Contigo Health and S2S Global to be in the range of $930 million to $1.02 billion. Declared Dividend • Aug 14
Third quarter dividend of US$0.21 announced Dividend of US$0.21 is the same as last year. Ex-date: 30th August 2024 Payment date: 15th September 2024 Dividend yield will be 4.3%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is not covered by earnings (123% earnings payout ratio). However, it is well covered by cash flows (41% cash payout ratio). The dividend has increased by an average of 2.5% per year over the past 4 years and payments have been stable during that time. The company's earnings per share (EPS) would need to grow by 36% to bring the payout ratio under control. EPS is expected to grow by 106% over the next 3 years, which is sufficient to bring the dividend into a sustainable range. Annuncio • Aug 09
Premier, Inc. Declares Quarterly Cash Dividend, Payable on September 15, 2024 Premier, Inc. announced that its Board of Directors declared a cash dividend of $0.21 per share of Class A common stock issued and outstanding. The cash dividend will be payable on September 15, 2024, to stockholders of record as of the close of business on September 1, 2024. Annuncio • Jul 23
Premier, Inc. to Report Q4, 2024 Results on Aug 20, 2024 Premier, Inc. announced that they will report Q4, 2024 results at 6:30 AM, US Eastern Standard Time on Aug 20, 2024 Recent Insider Transactions Derivative • Jul 21
Key Executive notifies of intention to sell stock Craig McKasson intends to sell 30k shares in the next 90 days after lodging an Intent To Sell Form on the 18th of July. If the sale is conducted around the recent share price of US$20.00, it would amount to US$600k. Since September 2023, Craig's direct individual holding has decreased from 316.76k shares to 178.61k. There have been no trades via on-market transactions or options from company insiders in the last 12 months. Recent Insider Transactions Derivative • Jul 04
Chief Operating Officer notifies of intention to sell stock Leigh Anderson intends to sell 20k shares in the next 90 days after lodging an Intent To Sell Form on the 1st of July. If the sale is conducted around the recent share price of US$18.68, it would amount to US$374k. Since September 2023, Leigh's direct individual holding has decreased from 203.93k shares to 183.93k. There have been no trades via on-market transactions or options from company insiders in the last 12 months. Recent Insider Transactions Derivative • Jun 13
General Counsel notifies of intention to sell stock David Klatsky intends to sell 13k shares in the next 90 days after lodging an Intent To Sell Form on the 10th of June. If the sale is conducted around the recent share price of US$18.55, it would amount to US$247k. Since September 2023, David's direct individual holding has decreased from 109.11k shares to 92.00k. Company insiders have collectively sold US$48k more than they bought, via options and on-market transactions in the last 12 months. Major Estimate Revision • May 26
Consensus EPS estimates fall by 12% The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate fell from US$1.05 to US$0.927 per share. Revenue forecast steady at US$1.31b. Net income forecast to grow 87% next year vs 28% growth forecast for Healthcare industry in the US. Consensus price target broadly unchanged at US$21.13. Share price fell 3.4% to US$18.99 over the past week. Upcoming Dividend • May 24
Upcoming dividend of US$0.21 per share Eligible shareholders must have bought the stock before 31 May 2024. Payment date: 15 June 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 4.4%. Lower than top quartile of American dividend payers (4.7%). Higher than average of industry peers (1.6%). Recent Insider Transactions Derivative • May 23
Chief Operating Officer notifies of intention to sell stock Leigh Anderson intends to sell 20k shares in the next 90 days after lodging an Intent To Sell Form on the 21st of May. If the sale is conducted around the recent share price of US$19.57, it would amount to US$391k. Since September 2023, Leigh's direct individual holding has decreased from 203.93k shares to 61.29k. Company insiders have collectively sold US$48k more than they bought, via options and on-market transactions in the last 12 months. Major Estimate Revision • May 14
Consensus EPS estimates fall by 30% The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate fell from US$1.50 to US$1.05 per share. Revenue forecast steady at US$1.31b. Net income forecast to grow 91% next year vs 27% growth forecast for Healthcare industry in the US. Consensus price target down from US$24.28 to US$21.38. Share price fell 4.9% to US$19.71 over the past week. Price Target Changed • May 09
Price target decreased by 7.6% to US$22.44 Down from US$24.28, the current price target is an average from 9 analysts. New target price is 14% above last closing price of US$19.61. Stock is down 27% over the past year. The company is forecast to post earnings per share of US$1.05 for next year compared to US$1.47 last year. 
